ANTICOAGULANT THERAPY IN PATIENTS WITH PROSTHETIC HEART VALVES

Download full text PDF
Issue: 
9
Year: 
2016

E. Gorbunova, MD; Professor O. Barbarash, MD Research Institute for Complex Problems of Cardiovascular Diseases, Kemerovo

The problem of anticoagulant therapy in patients with prosthetic heart valves (PHV) is due to the type of a prosthesis, on the one hand, and to the differences in a drug response to the indirect anticoagulant warfarin, caused by external, internal, and genetic factors, on the other. So far the problems associated with the quality of controlling the level of hypocoagulation have not been solved; the use of pharmacogenetic tests relevant for warfarin susceptibility has been limited; approaches to enhancing treatment adherence in patients with PHV have not been elaborated.

Keywords: 
cardiology
problems
anticoagulant therapy
prosthetic heart valves



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Dzemeshkevich S.L., Panchenko E.P. Antikoaguljantnaja terapija u patsien tov s klapannymi porokami serdtsa // Rus. med. zhurn. – 2001; 10: 427–30.
  2. Natsional'nye rekomendatsii po vedeniju, diagnostike i lecheniju klapannyh porokov serdtsa / M.: Izd-vo NTsSSH im. A.N. Bakuleva RAN, 2009; 356 s.
  3. Thourani V., Gunter R., Hurst S. et al. Postoperative warfarin following mitral valve repair or bioprosthetic valve replacement // J. Heart Valve Dis. – 2013; l22 (5): 716–23.
  4. Myrdko T., Sniezek-Maciejewska M., Rudzinski P. et al. Efficacy of intraoperative radiofrequency ablation in patients with permanent atrial fibrillation undergoing concomitant mitral valve replacement // Kardiol. Pol. – 2008; 66 (9): 932–8.
  5. Bokerija L.A., Nikonov S.F., Olofinskaja I.E. Hirurgicheskoe lechenie zabolevanij serdtsa u bol'nyh pozhilogo vozrasta: sovremennye podhody k lecheniju, kachestvo zhizni i prognoz / M.: NTsSSH im. A.N. Bakuleva RAMN 2012; 120 s.
  6. Gorbunova E.V. Puti povyshenija effektivnosti i bezopasnosti anti- koaguljantnoj terapii u patsientov s protezami klapanov serdtsa. Avtoref. dis. … d-ra med. nauk. Kemerovo, 2015; 46 s.
  7. Araki Y., Oshima H., Usui A. et al. Long-term results of the Maze procedur in patients with mechanical valve // Gen. Thorac. Cardiovasc. Surg. – 2012; 60 (6): 326–33.
  8. Szalay Z., Skwara W., Kloevekorn W. et al. Long-term follow-up after the mini-maze procedure // Ann. Thorac. Surg. – 2004; 77: 1277–81.
  9. Eikelboom J., Connolly S., Brueckmann M. Dabigatran versus warfarin in patients with mechanical heart valves // N. Engl. J. Med. – 2013; 369: 1206–14.
  10. Baron T., Kamath P., McBane R. Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures // N. Engl. J. Med. – 2013; 368 (22): 2113–24.
  11. Momot A.P., Bespalova O.V., Vorob'eva E.N. Effektivnost' terapii neprjamymi antikoaguljantami: rol' soderzhanija vitamina K v pischevyh pro- duktah // Ratsional'naja farmakoter. – 2006; 3: 51–5.
  12. Lechenie oral'nymi antikoaguljantami. Metodicheskie rekomendatsii / M.: GOU VPO «MGMSU Roszdrava», GOU VPO «MMA im. I.M. Sechenova», 2009; 48 s.
  13. Kong M., Lim T., Ng H. et al. Feasibility, cost-effectiveness and patient acceptance of point-of-care INR testing in a hospital-based anticoagulation clinic // Ann. Hematol. – 2008; 87 (11): 905–10.
  14. Brehm K, Schack J., Heilmann C. et al. Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism // Eur. J. Cardiothorac. Surg. – 2013; 44 (2): 309–14.
  15. Sychev D.A., Antonov I.M., Ignat'ev I.V. i dr. Antikoaguljantnoe dej- stvie i bezopasost' primenenija varfarina pri ego dozirovanii, osnovan- nom na rezul'tatah farmakogeneticheskogo testirovanija: rezul'taty pervogo rossijskogo prospektivnogo issledovanija // Kardiologija. – 2010; 5: 42–6.
  16. Ferder N., Eby C., Deych E. et al. Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. // J. Thromb. Haemost. – 2010; 8: 95–100.
  17. Van Berkel M., Crannage A., Murphy J. Evaluation of education on the appropriate use of vitamin k in warfarin reversal in adult inpatients // Hosp. Pharm. – 2013; 48 (8): 662–7.
  18. Chambers S., Chadda S., Plumb J. How much does international normalized ratio monitoring cost during oral anticoagulation with a vitamin K antagonist? A systematic review // Int. J. Lab. Hematol. – 2010; 32 (4): 427–42.
  19. Nutescu E., Bathija S., Sharp L. et al. Anticoagulation patient selfmonitoring in the United States: considerations for clinical practice adoption // Pharmacotherapy. – 2011; 31 (12): 1161–74.
  20. Rajpura J., Nayak R. Medication adherence in a sample of elderly suffering from hypertension: evaluating the influence of illness perceptions, treatment beliefs, and illness burden // J. Manag. Care Pharm. – 2014; 19 (1):
  21. 58–65.